Cytek Biosciences (CTKB) CTO Ming Yan Sells 135,892 Shares
CTKB's Chief Technology Officer Ming Yan sold 135,892 shares on June 12, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Ming Yan, CHIEF TECHNOLOGY OFFICER at Cytek Biosciences, Inc. ($CTKB), sold 135,892 shares on June 12, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CTKB is down 2.5% after 1 week, up 13.9% after 1 month and up 32.6% to date (from the $3.96 close on Jun 12, 2026).
CTKB
Cytek Biosciences, Inc.
Key Points
- On June 12, 2026, CTKB's Chief Technology Officer Ming Yan sold 135,892 shares.
- Shares of CTKB traded near $3.93, with significant institutional activity from BlackRock and Millennium Management.
- Analysts from Stephens & Co. and Morgan Stanley maintained their ratings with price targets of $4.75 and $5.5, respectively.
Get $CTKB trade alerts by text
We text you when insiders, Congress or big funds trade $CTKB. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Cytek Biosciences, Inc. alert may contain errors. Disclosures
CTKB's Chief Technology Officer, Ming Yan, sold 135,892 shares on June 12, 2026. This move comes amid a period of notable institutional trading activity around the company's stock.
Other Institutional Activity in CTKB
Several institutional investors have been active in CTKB. BlackRock, Inc. reduced its holdings by 165,759 shares, leaving it with 17,007,269 shares valued at approximately $74.3 million. Topline Capital Management, LLC also cut back, selling 377,985 shares to hold 7,064,481 shares worth about $30.9 million. On the other hand, Millennium Management LLC significantly increased its position, adding 1,539,351 shares to reach a total of 6,291,798 shares, valued at $27.5 million. Boston Partners also expanded its stake by 794,464 shares, ending with 5,802,773 shares valued at $25.4 million.
Cytek Biosciences, Inc. Stock Down 25.8%
Shares of CTKB traded near $3.93 recently. The stock has seen varied interest from institutional investors, reflecting diverse strategies around its valuation and market position.
Insider Buying and Selling at Cytek Biosciences, Inc.
In addition to Ming Yan's transaction, several other insiders were active. Vera Imper purchased 43,973 shares on June 10, 2026. Richard Chin, Michael Holder, and Deborah Neff each bought 18,261 shares on the same day. Michael Holder made an additional purchase of 43,973 shares.
Analysts Set New Price Targets
Analysts have been maintaining their positions on CTKB. On May 13, 2026, Stephens & Co. reiterated its 'buy' rating with a $4.75 price target. Morgan Stanley maintained a 'hold' rating with a $5.5 target on May 12, 2026. Earlier in the year, TD Cowen also kept a 'buy' rating with a $5.0 target.
About CTKB
CTKB operates in a dynamic sector, focusing on innovative solutions and technologies. The company is known for its commitment to developing and enhancing products that meet evolving market demands. CTKB's efforts are led by a team of experienced professionals dedicated to maintaining the company's competitive edge in the industry.
Bottom Line
The recent insider sale by Ming Yan and the varying institutional adjustments highlight the dynamic movements in CTKB's stock. Investors often watch these activities closely to gauge market sentiment and potential future performance. As always, it's important to remember that insider and institutional transactions are historical data and may not reflect current positions or future actions.
Related Filing Alerts
Source: Ming Yan's Form 4 filing on $CTKB (Jun 12, 2026). Find the original filing: CTKB Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts